Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the following new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Apidra SoloStar
Active Ingredient: Insulin glulisine 3.49mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: sanofi-aventis new zealand limited
Manufacturer: Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany
Product: Apidra
Active Ingredient: Insulin glulisine 3.49mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: sanofi-aventis new zealand limited
Manufacturer: Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany
Product: Doxine
Active Ingredient: Doxycycline hyclate 115mg equivalent to Doxycycline 100mg
Dosage Form: Tablet
New Zealand Sponsor: Pacific Pharmaceuticals Limited (part of Mylan)
Manufacturer: Intas Pharmaceuticals Limited, Matoda, Gujarat, India
Product: Taxotere
Active Ingredient: Docetaxel trihydrate 40mg/mL
Dosage Form: Solution for concentrate for infusion
Diluent
New Zealand Sponsor: sanofi-aventis new zealand limited
Manufacturers: Aventis Pharma, Dagenham, Essex, United Kingdom
Pierre Fabre Medicament Production, Etablissement Aquitaine Pharm International, Idron, France
Sanofi Chimie, Vitry-Sur-Seine, France
Dated this 4th day of September 2008.
ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).